证券代码：300314 证券简称：戴维医疗 公告编号：2025-034 宁波戴维医疗器械股份有限公司 关于全资子公司申报医疗器械注册获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁波 维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得由浙江省 药品监督管理局颁发的3项《受理通知书》，受理号为：械受20254019912、 械受20254019913、械受20254019722。具体情况如下： | 序号 | 产品名称 | 注册分 类 | | 临床用途 | | --- | --- | --- | --- | --- | | 1 | | | | 本产品适用于肺结节患者接受胸腔镜手术前的 CT | | | 一次性使用肺结节定 位穿刺针 | II | 类 | 引导下的肺结节定位，带线锚钩留置体内时间小于 | | | | | | 24 小时。 | | 2 | 一次性使用电子输尿 管肾盂内窥镜导管 | II | 类 | 本产品与本公司电子内窥镜图像处理器配合使用， 通过视频监视器提供影像，用 ...

Group 1 - Xiansheng Pharmaceutical announced that its insomnia treatment drug Daridorexant (brand name: Kewiko®) has been approved for marketing in China, enhancing patient access and supporting long-term use [1] - HAP Pharmaceutical entered a global strategic collaboration with Otsuka Pharmaceutical to develop a BCMAxCD3 bispecific T-cell engager, receiving an upfront payment of $47 million and potential additional payments up to $623 million based on future milestones [1] - Baotai announced a licensing agreement with Stein for the commercialization rights of BAT2406 (Dupilumab) in Latin America, with total upfront and milestone payments potentially reaching $10 million [1] Group 2 - David Medical received a medical device registration certificate for its electric stretcher, which offers significant advantages over traditional manual devices, improving operational efficiency and reducing the burden on healthcare personnel [2] - Hanyu Pharmaceutical's subsidiary received approval for the listing of its active pharmaceutical ingredient Acetate Degarelix, which is used to treat advanced prostate cancer [3] - China Traditional Chinese Medicine reported that its innovative TCM drug Yushudapin's registration application has been accepted, showing significant efficacy in improving early symptoms of depressive disorders [4]

Core Viewpoint - David Medical (300314) has received the Medical Device Registration Certificate from the Zhejiang Provincial Drug Administration for its new product, the electric stretcher, which will enhance the company's pre-hospital emergency and in-hospital transfer solutions [1] Group 1 - The acquisition of the electric stretcher will fill a product gap in the emergency equipment sector for the company [1] - This new product will enrich the company's product line and improve its core competitiveness [1] - The positive impact on the company's future operating results is anticipated due to this development [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-033 宁波戴维医疗器械股份有限公司 关于新产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，宁波戴维医疗器械股份有限公司（以下简称"公司"）的新产 品电动担架车获得了浙江省药品监督管理局颁发的《医疗器械注册证》， 具体如下： 一、医疗器械注册证的具体情况 产品名称：电动担架车 型号、规格：DJ-100、DJ-100A、DJ-100B、DJ-100C 注册证编号：浙械注准20252151458 适用范围：用于医疗机构运送、移动患者用。 二、新产品的市场状况 随着医疗科技革新与临床需求升级，智能化急救设备已成为现代医疗 体系的重要支撑。电动液压担架车相较于传统手推式设备，在临床场景中 展现出显著优势，其电动液压升降系统能够实现平稳、快速的升降操作， 减少了传统手动操作中可能出现的颠簸和不适，同时也减少医护人员手动 操作的强度，减轻医护负担。该产品医疗器械注册证的取得将完善公司院 前急救-院内转运全链路解决方案，填补公司在急救设备领域的产品空白。 三、对公司的影响 以 ...

本公司2024年年度权益分派方案为：以公司现有总股本288,000,000 股为基数，向全体股东每10股派0.870000元人民币现金（含税；扣税后， 通过深股通持有股份的香港市场投资者、境外机构（含QFII、RQFII）以及 持有首发前限售股的个人和证券投资基金每10股派0.783000元；持有首发 后限售股、股权激励限售股及无限售流通股的个人股息红利税实行差别化 税率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股 期限计算应纳税额【注】；持有首发后限售股、股权激励限售股及无限售 流通股的证券投资基金所涉红利税，对香港投资者持有基金份额部分按10% 征收，对内地投资者持有基金份额部分实行差别化税率征收）。 二、权益分派方案 在分配方案实施前，若公司股本发生变化的，公司将按照"分红总额 不变"的原则，对分配比例进行调整。 生变化。 超过两个月。 证券代码：300314 证券简称：戴维医疗 公告编号：2025-032 宁波戴维医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）202 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-032 宁波戴维医疗器械股份有限公司 2024年年度权益分派实施公告 4、本次实施权益分派距离公司股东大会审议通过权益分派方案时间未 超过两个月。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本288,000,000 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）2024年年度权 益分派方案已获2025年5月6日召开的2024年度股东大会审议通过，现将权 益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司2024年年度股东大会审议通过的2024年年度权益分派方案为： 以截至2024年12月31日公司总股本288,000,000股为基数，向全体股东每10 股派发现金红利0.87元人民币（含税），共计派发现金红利人民币 25,056,000.00元（含税），本次利润分配不送红股，不以资本公积金转增 股本，剩余未分配利润结转以后年度分配。 在分配方案实施前，若公司股本发生变化的，公司将按照"分红总额 不变"的原则 ...

Core Viewpoint - The electric laparoscopic stapler market in China is experiencing growth due to increasing demand for minimally invasive surgeries, despite facing challenges from centralized procurement policies leading to a market size decline in 2024 [1][14]. Overview - Staplers are essential high-value consumables in modern surgery, replacing manual suturing with devices that use titanium staples for tissue connection [2][14]. - The demand for electric laparoscopic staplers is rising as the number of minimally invasive surgeries increases, driven by an aging population and higher expectations for medical service quality [1][14]. Market Policy - The Chinese government has implemented various policies to support the development of the medical device industry, including electric laparoscopic staplers, creating a favorable environment for market growth [6][9]. Industry Chain - The upstream of the electric laparoscopic stapler industry includes suppliers of metals like stainless steel and titanium, as well as polymer materials and components like firing mechanisms and motors [10]. - The midstream involves the research and production of electric laparoscopic staplers, while the downstream focuses on medical institutions that utilize these devices [10]. Development Status - The market for electric laparoscopic staplers is projected to decline to 3.72 billion yuan in 2024, a decrease of 7.38% year-on-year, due to the impact of centralized procurement policies [1][14]. Competitive Landscape - The market for electric laparoscopic staplers in China is relatively stable, with higher entry barriers compared to manual types, and domestic manufacturers are increasingly competing with established international brands [16][19]. - As of May 2025, a total of 210 electric laparoscopic stapler approvals have been granted by the National Medical Products Administration in China [16]. Industry Representative Companies - Jiangsu Fenghe Medical Equipment Co., Ltd. focuses on the development and production of disposable surgical consumables, contributing to advancements in minimally invasive surgery [19]. - Ningbo David Medical Devices Co., Ltd. has a comprehensive product matrix, including electric laparoscopic staplers, and reported a revenue of 5.27 billion yuan in 2024, with 1.887 billion yuan from minimally invasive surgical instruments [21]. Development Trends - Future advancements in electric laparoscopic staplers are expected to integrate sensor and artificial intelligence technologies, enhancing automation and precision in surgical procedures [23].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - As of June 5, 2023, David Medical's stock closed at 12.62 yuan, down 1.48%, with a rolling price-to-earnings (PE) ratio of 87.11 times, and a total market capitalization of 3.635 billion yuan [1] - The company operates in the medical device industry, specifically focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1] Group 2 - In the first quarter of 2025, David Medical reported operating revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year, with a gross profit margin of 57.13% [2] - The average PE ratio for the medical device industry is 50.97 times, with a median of 36.67 times, positioning David Medical at the 102nd rank within the industry [2] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and various accolades in Zhejiang Province for its credit management and specialized innovation [1]

Core Viewpoint - David Medical's stock closed at 12.77 yuan, up 2.49%, with a rolling PE ratio of 88.15, marking a new low in 39 days, and a total market value of 3.678 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78%, with a gross profit margin of 57.13% [2] - The company ranks 102nd in the industry based on PE ratio, with an industry average of 50.80 and a median of 36.71 [2] Group 2: Market Position and Recognition - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators and neonatal monitoring devices [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1]

内容概要：随着我国医疗水平的不断提高，越来越多的医疗机构采购婴儿培养箱以满足临床治疗需求， 此外，随着国民生活水平提高，对医疗保健的投入增加，特别是对新生儿护理的重视程度不断提升，愿 意为婴儿培养箱等相关医疗设备支付更高的费用，在此背景下，我国婴儿培养箱市场发展迅速，2024 年，随着一系列医疗器械集中采购政策全面落地实施，对我国婴儿培养箱行业发展产生了深刻的影响， 一方面使婴儿培养箱的需求及接纳程度明显提升，另一方面，受集采降价影响我国婴儿培养箱行业市场 规模有所下滑，据统计，2024年我国婴儿培养箱行业市场规模降至4.15亿元，同比减少4.06%。 上市企业：戴维医疗（300314）、莲池医院（831672.NQ）、华润医疗（01515.HK） 相关企业：深圳市科曼医疗设备有限公司、上海力申科学仪器有限公司、北京巨龙三优科技有限公司、 郑州迪生仪器仪表有限公司、苏州贝茵科技股份有限公司、深圳百生德科技有限公司、山东博科保育科 技股份有限公司 关键词：婴儿培养箱市场政策、婴儿培养箱产业链、汽婴儿培养箱市场规模、婴儿培养箱竞争格局、婴 儿培养箱发展趋势 一、概述 婴儿培养箱控制系统采用计算机技术对箱内温度（箱 ...